EUVIMEDEUVIMED entdecken
Open Access

Transcriptional Profiling and Consensus Molecular Subtype Assignment to Understand Response and Resistance to Anti–Epidermal Growth Factor Receptor Therapy in Colorectal Cancer

Saikat Chowdhury iD, Ria Gupta, Joshua Millstein iD, Kangyu Lin iD, Valsala Haridas, Mohammad A Zeineddine iD, Christine Parseghian iD, Heinz-Josef Lenz iD, Scott Kopetz iD, John Paul Shen iD

JCO Precision Oncology · 2023

DOI: 10.1200/po.22.00422 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Precision Oncology, 2023. Verfasst von Saikat Chowdhury und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX. Hauptthemen laut MEDLINE: Colorectal Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Activating mutations in KRAS, NRAS, and BRAF are known to cause resistance to anti–epidermal growth factor receptor (EGFR) therapy; however, only approximately 40% of patients with colorectal cancer (CRC) with RAS WT tumors respond to anti-EGFR treatment. We sought to discover novel biomarkers to predict response to anti-EGFR antibody treatment in CRC and to understand mechanisms of resistance to anti-EGFR therapy. MATERIALS AND METHODS Transcriptomic profiles from three clinical and two preclinical cohorts treated with cetuximab were used to assign consensus molecular subtypes (CMS) to each sample and correlated with outcomes. RESULTS Restricting to RAS WT patients, we observed that CMS2 tumors (canonical subtype) had significantly higher response rates relative to other CMS when treated with cetuximab combination with doublet chemotherapy (Okita et al cohort: 92% disease control rate (DCR) for CMS2, chi-square P = .04; CALGB/SWOG 80405 cohort: 90% objective response rate (ORR) for CMS2, chi-square P < .001) and with single-agent cetuximab (68%, chi-square P = .01). CMS2 tumors showed best response among right-sided (ORR = 80%) and left-sided (ORR = 92%) tumors in the CALGB/SWOG 80405 cohort. CMS2 cells lines were most likely to be sensitive to cetuximab (60%) and CMS2 patient-derived xenograft had the highest DCR (84%). We found Myc, E2F, and mammalian target of rapamycin pathways were consistently upregulated in resistant samples (enrichment score >1, false discovery rate

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsHumansCetuximabReceptors, Growth Factor

Substanzen

CetuximabReceptors, Growth Factor

Autor:innen und Institutionen

  • Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Department of Population and Public Health Sciences, Keck School of Medicine of USC, Los Angeles, CA.
  • University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA.

ORCID-Profile: Saikat Chowdhury, Joshua Millstein, Kangyu Lin, Mohammad A Zeineddine, Christine Parseghian, Heinz-Josef Lenz, Scott Kopetz, John Paul Shen

Förderung

  • NCI NIH HHS

Zitieren

APA

Chowdhury, S., Gupta, R., Millstein, J., Lin, K., Haridas, V., Zeineddine, M. A., Parseghian, C., Lenz, H. J., Kopetz, S., & Shen, J. P. (2023). Transcriptional Profiling and Consensus Molecular Subtype Assignment to Understand Response and Resistance to Anti–Epidermal Growth Factor Receptor Therapy in Colorectal Cancer. JCO Precision Oncology. https://doi.org/10.1200/po.22.00422

Vancouver

Chowdhury S, Gupta R, Millstein J, Lin K, Haridas V, Zeineddine MA, et al. Transcriptional Profiling and Consensus Molecular Subtype Assignment to Understand Response and Resistance to Anti–Epidermal Growth Factor Receptor Therapy in Colorectal Cancer. JCO Precision Oncology. 2023. doi:10.1200/po.22.00422

BibTeX
@article{Chowdhury2023,
  author = {Chowdhury, Saikat and Gupta, Ria and Millstein, Joshua and Lin, Kangyu and Haridas, Valsala and Zeineddine, Mohammad A and Parseghian, Christine and Lenz, Heinz-Josef and Kopetz, Scott and Shen, John Paul},
  title = {Transcriptional Profiling and Consensus Molecular Subtype Assignment to Understand Response and Resistance to Anti–Epidermal Growth Factor Receptor Therapy in Colorectal Cancer},
  journal = {JCO Precision Oncology},
  year = {2023},
  doi = {10.1200/po.22.00422}
}
Kostenlos starten →